Share on StockTwits

Oxford BioMedica plc (LON:OXB)‘s stock had its “buy” rating reaffirmed by analysts at N+1 Singer in a research report issued to clients and investors on Wednesday. They currently have a GBX 3.30 ($0.06) target price on the stock. N+1 Singer’s target price indicates a potential upside of 20.00% from the stock’s previous close.

Shares of Oxford BioMedica plc (LON:OXB) traded up 0.92% on Wednesday, hitting GBX 2.75. 1,941,260 shares of the company’s stock traded hands. Oxford BioMedica plc has a 52 week low of GBX 1.356 and a 52 week high of GBX 3.615. The stock’s 50-day moving average is GBX 2.13 and its 200-day moving average is GBX 2.53. The company’s market cap is £38.9 million.

A number of other firms have also recently commented on OXB. Analysts at Oriel Securities Ltd reiterated an “add” rating on shares of Oxford BioMedica plc in a research note on Wednesday, June 18th. Separately, analysts at Edison Investment Research reiterated a “neutral” rating on shares of Oxford BioMedica plc in a research note on Thursday, April 17th. Finally, analysts at Nplus1 Brewin reiterated a “hold” rating on shares of Oxford BioMedica plc in a research note on Thursday, April 10th. They now have a GBX 3.30 ($0.06) price target on the stock.

Oxford BioMedica plc (LON:OXB) is a biopharmaceutical company developing gene-based medicines and therapeutic vaccines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.